{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T02:27:30Z","timestamp":1779416850285,"version":"3.53.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["L248022"],"award-info":[{"award-number":["L248022"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"CAMS Innovation Fund for Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jhepr.2026.101816","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T23:32:44Z","timestamp":1772926364000},"page":"101816","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of immune checkpoint inhibitors in patients with high microsatellite instability\/mismatch repair\u2013deficient advanced cholangiocarcinoma: A propensity score\u2013matched study"],"prefix":"10.1016","volume":"8","author":[{"given":"Mingjian","family":"Piao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiongyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyue","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuofeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3444-8044","authenticated-orcid":false,"given":"Haitao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2026.101816_bib1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.pharmthera.2018.04.004","article-title":"DNA mismatch repair in cancer","volume":"189","author":"Baretti","year":"2018","journal-title":"Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.jhepr.2026.101816_bib2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41571-025-01015-z","article-title":"Epidemiology, pathogenesis, biology and evolving management of MSI-H\/dMMR cancers","volume":"22","author":"Ambrosini","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101816_bib3","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12916-024-03257-7","article-title":"Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma","volume":"22","author":"Yang","year":"2024","journal-title":"BMC Med"},{"issue":"4","key":"10.1016\/j.jhepr.2026.101816_bib4","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1158\/1078-0432.CCR-15-1678","article-title":"Microsatellite instability as a biomarker for PD-1 blockade","volume":"22","author":"Dudley","year":"2016","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"4","key":"10.1016\/j.jhepr.2026.101816_bib5","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1053\/j.gastro.2008.01.015","article-title":"Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers","volume":"134","author":"Schwitalle","year":"2008","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101816_bib6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","article-title":"The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints","volume":"5","author":"Llosa","year":"2015","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.jhepr.2026.101816_bib7","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41568-024-00705-7","article-title":"Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours","volume":"24","author":"Holder","year":"2024","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"10.1016\/j.jhepr.2026.101816_bib8","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio","year":"2022","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101816_bib9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40364-023-00535-z","article-title":"Biomarkers and prognostic factors of PD-1\/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma","volume":"12","author":"Zhang","year":"2024","journal-title":"Biomark Res"},{"issue":"4","key":"10.1016\/j.jhepr.2026.101816_bib10","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1159\/000543994","article-title":"Conversion surgery after immune checkpoint inhibitor-based combination therapy for initially unresectable hepatocellular carcinoma: a retrospective cohort study","volume":"14","author":"Piao","year":"2025","journal-title":"Liver Cancer"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101816_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"10.1016\/j.jhepr.2026.101816_bib12","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3350\/cmh.2021.0287","article-title":"Intrahepatic cholangiocarcinoma: tumour heterogeneity and its clinical relevance","volume":"28","author":"Komuta","year":"2022","journal-title":"Clin Mol Hepatol"},{"issue":"6","key":"10.1016\/j.jhepr.2026.101816_bib13","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.jhep.2022.07.022","article-title":"Current epidemiology of cholangiocarcinoma in Western countries","volume":"77","author":"Vithayathil","year":"2022","journal-title":"J Hepatol"},{"issue":"10391","key":"10.1016\/j.jhepr.2026.101816_bib14","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet Lond Engl"},{"issue":"8","key":"10.1016\/j.jhepr.2026.101816_bib15","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101816_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/17562848221117638","article-title":"Expression of PD-L1 as a predictive marker of sensitivity to immune checkpoint inhibitors in patients with advanced biliary tract cancer","volume":"15","author":"Kim","year":"2022","journal-title":"Ther Adv Gastroenterol"},{"issue":"6","key":"10.1016\/j.jhepr.2026.101816_bib17","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1213\/ANE.0000000000005773","article-title":"Statistics from A (agreement) to Z (z score): a guide to interpreting common measures of association, agreement, diagnostic accuracy, effect size, heterogeneity, and reliability in medical research","volume":"133","author":"Schober","year":"2021","journal-title":"Anesth Analg"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101816_bib18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3892\/ol.2021.13122","article-title":"Low prevalence of biliary tract cancer with defective mismatch repair genes in a Japanese hospital-based population","volume":"23","author":"Ando","year":"2022","journal-title":"Oncol Lett"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101816_bib19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41416-018-0199-2","article-title":"Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma","volume":"120","author":"Goeppert","year":"2019","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101816_bib20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41698-025-01096-0","article-title":"Applying next-generation sequencing to detect microsatellite instability in pan-cancer patients: a retrospective study of 35,563 Chinese cases","volume":"9","author":"Shang","year":"2025","journal-title":"Npj Precis Oncol"},{"key":"10.1016\/j.jhepr.2026.101816_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104224","article-title":"Practical guidelines for molecular testing of cholangiocarcinoma in clinical practice: Italian experts\u2019 position paper","volume":"194","author":"Fassan","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"issue":"19","key":"10.1016\/j.jhepr.2026.101816_bib22","doi-asserted-by":"crossref","first-page":"4831","DOI":"10.3390\/cancers15194831","article-title":"Mismatch repair deficiency is a prognostic factor predicting good survival of opisthorchis viverrini-associated cholangiocarcinoma at early cancer stage","volume":"15","author":"Khuntikeo","year":"2023","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.jhepr.2026.101816_bib23","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.jhepr.2026.101816_bib24","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/bjc.2016.64","article-title":"Quality of life, long-term survivors and long-term outcome from the ABC-02 study","volume":"114","author":"Bridgewater","year":"2016","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.jhepr.2026.101816_bib25","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.3390\/ijms19051421","article-title":"Microsatellite instability occurs rarely in patients with cholangiocarcinoma: a retrospective study from a German tertiary care hospital","volume":"19","author":"Winkelmann","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhepr.2026.101816_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115670","article-title":"Real-world efficacy of immune checkpoint inhibitors in microsatellite unstable\/mismatch repair-deficient biliary tract cancer: an AGEO study","volume":"227","author":"Campo-Le-Brun","year":"2025","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.jhepr.2026.101816_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011436","article-title":"Efficacy of immunotherapy in gastrointestinal (GI) tumors with mismatch repair deficient (MMRd) unusual phenotype: an AGEO real-world study","volume":"13","author":"Alouani","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jhepr.2026.101816_bib28","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ejca.2022.07.020","article-title":"Deficient mismatch repair\/microsatellite unstable colorectal cancer: diagnosis, prognosis and treatment","volume":"175","author":"Taieb","year":"2022","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.jhepr.2026.101816_bib29","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.immuni.2016.02.025","article-title":"Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability","volume":"44","author":"Mlecnik","year":"2016","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101816_bib30","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40164-023-00470-7","article-title":"Molecular profiling of biliary tract cancers reveals distinct genomic landscapes between circulating and tissue tumor DNA","volume":"13","author":"Astier","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.jhepr.2026.101816_bib31","article-title":"Targeting WEE1 in ARID1A\/TP53 concurrent mutant colorectal cancer by exploiting RLoop accumulation and DNA repair deficiencies","volume":"30","author":"Zhang","year":"2025","journal-title":"Adv Sci Weinh Baden-wurtt Ger"},{"issue":"8","key":"10.1016\/j.jhepr.2026.101816_bib32","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.7150\/thno.100793","article-title":"PBRM1 deficiency enhances PD1 immunotherapeutic sensitivity via chromosomal accessibility in colorectal cancer","volume":"15","author":"Li","year":"2025","journal-title":"Theranostics"},{"issue":"12","key":"10.1016\/j.jhepr.2026.101816_bib33","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1158\/2159-8290.CD-19-1448","article-title":"CRISPR-GEMM pooled mutagenic screening identifies KMT2D as a major modulator of immune checkpoint blockade","volume":"10","author":"Wang","year":"2020","journal-title":"Cancer Discov"},{"issue":"24","key":"10.1016\/j.jhepr.2026.101816_bib34","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-25-0952","article-title":"LRP1b loss predicts sensitivity to immunotherapy in patients with NSCLC: an analysis of the phase III CheckMate-026 randomized trial","volume":"31","author":"Armstrong","year":"2025","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101816_bib35","first-page":"75","article-title":"Comprehensive genetic variant analysis reveals combination of KRAS and LRP1B as a predictive biomarker of response to immunotherapy in patients with non-small cell lung cancer","volume":"44","author":"Eklund","year":"2025","journal-title":"J Exp Clin Cancer Res CR"},{"issue":"3_suppl","key":"10.1016\/j.jhepr.2026.101816_bib36","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1200\/JCO.2021.39.3_suppl.321","article-title":"Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study","volume":"39","author":"Villanueva","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258955592600087X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258955592600087X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T01:49:36Z","timestamp":1779414576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258955592600087X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S258955592600087X"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101816","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of immune checkpoint inhibitors in patients with high microsatellite instability\/mismatch repair\u2013deficient advanced cholangiocarcinoma: A propensity score\u2013matched study","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101816","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101816"}}